Streetbeat News

VVOS

Vivos Therapeutics, Inc.

Industry

Medical - Devices

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Open

3.25

Mkt cap

19M

Volume

50K

High

3.33

P/E Ratio

-0.66

52-wk high

6.28

Low

3.10

Div yield

N/A

52-wk low

1.91

Vivos Therapeutics, Inc. has received FDA 510(k) clearance for its CARE oral appliances, designed to treat severe obstructive sleep apnea in adults. This includes the DNA, mRNA, and mmRNA oral appliances, marking a significant milestone for the company in the medical device and technology sector.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:32 pm

Vivos Therapeutics, Inc. (VVOS) reported a narrower loss of $(1.75) per share in Q3 compared to $(6.50) per share in the same quarter last year, indicating an improvement in earnings. However, the company experienced a decline in sales, reporting $3.30 million this quarter, a 22.26% decrease from $4.25 million in the same period last year.

Portfolio Pulse from totan@benzinga.com

November 14, 2023 | 9:22 pm

The article lists a number of companies scheduled to report their earnings on November 14, 2023. It includes their expected quarterly results, with some companies anticipated to report profits per share and others expected to report losses. The revenues for each company are also provided, giving investors insights into the financial performance of these companies for the upcoming earnings announcements.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:23 pm

Vivos Therapeutics has announced the pricing of a $4 million private placement, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 4:02 pm

Vivos Therapeutics (NASDAQ:VVOS) has announced a private placement of 980,393 shares at $4.08 per share, priced at-the-market under Nasdaq rules. The company will also issue a five-year Series A Warrant and an 18-month Series B Warrant to purchase up to an aggregate of 980,393 shares of common stock each. The gross proceeds from the offering are expected to be approximately $4.0 million, which will be used for general corporate purposes. The closing of the private placement is expected to occur on November 2, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:11 pm

The article lists the stocks that gained and lost the most in Friday's mid-day session. Notable gainers include Apollomics, BIO-key International, SeaStar Medical Holding, NerdWallet, and ImmunityBio. Among the losers were Siyata Mobile, reAlpha Tech, Medicenna Therapeutics, Fujian Blue Hat Interactive Entertainment Technology, and Vivos Therapeutics. Barnes Group shares fell by around 28% due to downbeat third-quarter earnings and a lowered FY23 outlook.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 5:17 pm

Vivos Therapeutics has announced a 1-for-25 reverse stock split, which will be effective from October 27. This move is typically aimed at increasing the per-share price of the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 11:34 am

During Tuesday's pre-market session, several health care stocks experienced significant movement. LianBio, TransCode Therapeutics, MyMD Pharmaceuticals, Vivos Therapeutics, Organovo Holdings, and Revelation Biosciences saw increases in their stock prices. Conversely, LumiraDx, INVO Bioscience, Oncology Institute, Citius Pharma, SAB Biotherapeutics, and TC BioPharm experienced decreases.

Portfolio Pulse from Benzinga Insights

October 24, 2023 | 1:06 pm

Vivos Therapeutics has signed a nationwide distribution agreement with Lincare. This deal will allow Vivos' products to be distributed across the country, potentially increasing the company's market reach and sales.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:32 am

Several healthcare stocks experienced significant movement in Monday's after-market session. Unicycive Therapeutics, BioSig Technologies, Amneal Pharmaceuticals, Esperion Therapeutics, GRI Bio, and Blue Water Biotech saw gains, while LumiraDx, SeaStar Medical Holding, CareDx, Vivos Therapeutics, Apollomics, and Sonendo experienced losses.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.